Ointment « Chondroxid» 5 %

Unguentum Chondroxidi 5 %

International nonproprietary name

Chondroitin sulfate.

Chondroitin sulfate.

Pharmacotherapeutic group

Corrector of osteal and cartilaginous tissue metabolism. The preparation for external application at painful syndrome at diseases of musculoskeletal   system.

 Composition  

1 g of ointment contains 50 mg of chondroitin sulfate, dimethylsulfoxide -100 mg.

Pharmacological action

Pharmacodynamics

Diclofenac sodiumis referred to nonsteroid antiinflammatory agents (NSAID), it is an inhibitor of prostaglandin biosynthesis. It relaxes a pain at a rest and at movement, morning stiffness, joints tumescence, improves their functional ability. Quickly relaxes both a spontaneous pain, and an oxycinesia, reduces inflammatory edema.

Dimethyl sulfoxideas a part of the ointmentform has anti-inflammatory, analgetic and fibrinolitic effect, promotes the best penetration of active substances (chondroitin) through cellular membranes.

Pharmakokinetics

At application of ointment on the intact skin chondroitin sulfate is absorbed poorly and do not have the expressed systemic action. The dimethyl sulfoxide with high rate gets through biological membranes, including the intact skin, mucous, environment of microbial cells. The products of metabolism are eliminated with urine and faeces, and also through lungs and skin.

Indications

Degenerative diseases of joints and backbone, osteoarthrosis, osteochondrosis.

Dosage and method of administration

Ointment is applied externally 2-3 times a day on the area of affected joint at the concentration of 1-2 gper 100-200 cm²of skin and is softly rubbed up to complete absorption. The column of ointment in 1 cm which have been squeezed out from a tuba corresponds to 0,3 g.

Contraindications

Hypersensitivity, predilection to bleeding sickness, thrombophlebites, pregnancy, the period of lactation (for the period of treatment breast feeding should be stopped).

Side effects

In rare cases allergic reactions, hyperemia and itch are possible. At occurrence of allergic reactions the treatment by the preparation should be withdrawn, it is necessary to carry out the desensitizing therapy in case of sharp reddening and itch.

Safety measures

The special safety measures are not required at application of «Chondroxid » ointment.

Interactions with other medicinal preparations

The cases of negative medicinal interaction at administration of «Chondroxid » ointment on a background of therapy by other medical products included in the standard schemes of joints and backbone degenerative diseases treatment are not established.

Overdosage

The phenomena of overdosage at application of the preparation are not described.

The form of release

30 gin aluminium tubas or glass vials.